Today: 27 February 2026
Subscribe
Browse Category

NASDAQ:TWST 7 August 2025 - 2 February 2026

Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience shares surged 14% to $46.88 Monday after posting record Q1 revenue of $103.7 million and raising its full-year forecast. Gross margin reached 52%, with net loss narrowing to $30.5 million. The company reaffirmed its target to reach adjusted EBITDA breakeven by late fiscal 2026. Investors are watching if Twist can sustain margins and meet its March-quarter revenue guidance.
2 February 2026
···
Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience stock jumps on early revenue beat as TWST investors eye JPM talk and Feb. 2 results

Twist Bioscience shares rose nearly 8% Monday after preliminary fiscal Q1 revenue reached about $103.7 million, beating company forecasts. DNA Synthesis and Protein Solutions sales climbed 27% to $51.1 million, while NGS Applications revenue hit $52.6 million. CEO Emily Leproust cited strong demand in both segments. Full audited results are due Feb. 2.
12 January 2026
··
Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience (TWST) Stock News Today: Forecasts, Analyst Targets, and Key Catalysts (Dec. 22, 2025)

Twist Bioscience shares rose about 5.4% to $34.26 midday Dec. 22, 2025, after new licensing deals and product expansions. The stock remains down roughly 26% year-to-date despite the rally. Recent catalysts include a licensing agreement with Aptamer Group for hot-start PCR and NGS products and continued integration with Element Biosciences’ AVITI system. TWST’s 52-week range spans $23.30 to $55.33.
22 December 2025
··
Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience shares rose about 6% to $33 by late morning Dec. 17 after new partnership news, recent product launches, and a Barclays price target hike to $39. The company signed a licensing deal with Aptamer Group for use in PCR and NGS products and launched new plasmid DNA preps. Investors are watching progress toward breakeven targeted for fiscal Q4 2026.
17 December 2025
··
DNA Drives, Glass Discs & 5D Crystals: The Race to Store Data Forever

DNA Drives, Glass Discs & 5D Crystals: The Race to Store Data Forever

DNA data storage can theoretically reach up to 1 zettabyte per gram and survive millennia, but writing remains slow and costly. In 2025, Twist Bioscience spun off Atlas Data Storage with $155 million to commercialize DNA storage, while Catalog built a fridge-sized encoder. Microsoft’s Project Silica glass discs now store up to 7 TB each, withstand extreme conditions, and are set for Azure pilots by 2026, outpacing DNA in practical deployment.
7 August 2025
··
Go toTop